Trial Profile
Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II trial Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2018
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms POSTCARD - GETUG-P13
- 04 Sep 2018 New trial record